AstraZeneca – A study that has been carried out by AstraZeneca which is such a giant pharmaceutical Company has reflected Brilinta as an effective drug that could treat DAPT and on long term basis. It has further said that the drug is one of the most recent anti-clotting drug.
Further to this, AstraZeneca has since said that long – term use of this drug will not only be used by those at the risk of heart attacks but it will also bring down risks of heart – related deaths.
“The results are very promising”. This is according to lead researcher Brigham and cardiologist Dr. Marc Sabatine.Sabatine has confirmed that there is consistency in the benefits being associated with this drug especially on the patients with heart health events.
The study was conducted on 21,000 patients put together from 31countries. However, the subject under study included people who had endured a heart attack previously and within three years. Besides, the same people would have suffered from diabetes attack or old age which would have exposed them to another risk of heart attack.
The administration of the drug was either 90mg, 60mg of the drug orplacebo. On the conclusion of the study, it was found that the risk of heart attack or heart-related death for those who had taken 90mg of Brilinta was at 15% which was against the 16% of those who had taken 60mg of the drug. This clearly illustrates that the 60mg has more benefits that the 90mg.
Most patients have since approved the use of 90mg of Brilinta on a double dose daily especially those with acute coronary syndrome. However, it doesn’t go without side effects. Some patients had raised concerns of bleeding after taking the drug while others indicated that it was causing shortness of breath in them.
Never the less the study which was under the funding of AstraZeneca itself according to experts was worth it since from the face value the results looked reliable.